



# SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

## STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & SIX MONTHS ENDED SEPTEMBER 30, 2020.

							Rs. In Lakhs
							STANDALONE
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 Months period ended		For the year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
		UN AUDITED	UN AUDITED	Refer No 8	UN AUDITED	Refer No 8	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	<b>Income</b>						
	Revenue from operations	897.96	142.86	138.73	1,040.82	298.22	1,441.47
	Other Income	227.72	252.93	238.10	480.65	518.39	1,403.63
	<b>Total income</b>	<b>1,125.68</b>	<b>395.79</b>	<b>376.83</b>	<b>1,521.47</b>	<b>816.61</b>	<b>2,845.10</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	486.15	340.67	420.11	826.82	869.07	1,459.51
	d) Finance costs	25.32	21.93	10.39	47.25	21.00	54.03
	e) Depreciation and amortisation expense	107.46	106.49	141.61	213.95	226.13	416.87
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	701.93	494.73	751.18	1,196.66	1,379.56	2,594.44
	h) Other Expenses	94.25	86.43	217.90	180.68	432.05	913.86
	<b>Total expenses</b>	<b>1,415.11</b>	<b>1,050.25</b>	<b>1,541.19</b>	<b>2,465.36</b>	<b>2,927.81</b>	<b>5,438.71</b>
3	Profit before exceptional items & Tax (1-2)	(289.43)	(654.46)	(1,164.36)	(943.89)	(2,111.20)	(2,593.61)
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	(289.43)	(654.46)	(1,164.36)	(943.89)	(2,111.20)	(2,593.61)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	197.18
	b) Deferred tax	(99.46)	(246.72)	(41.11)	(346.18)	(1,442.38)	(1,415.47)
7	Net Profit/ (Loss) for the period/ year(5-6)	(189.97)	(407.74)	(1,123.25)	(597.71)	(668.82)	(1,375.32)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(11.35)	(11.35)	(1.06)	(22.70)	(2.12)	(45.41)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.96	3.97	0.37	7.93	0.74	15.87
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(7.39)</b>	<b>(7.38)</b>	<b>(0.69)</b>	<b>(14.77)</b>	<b>(1.38)</b>	<b>(29.54)</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>(197.36)</b>	<b>(415.12)</b>	<b>(1,123.94)</b>	<b>(612.48)</b>	<b>(670.20)</b>	<b>(1,404.86)</b>
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity		-	-	-	-	37,494.53
12	Earning Per Share (EPS) (Face value of Rs.1/- each)						
	a) Basic	(0.15)	(0.32)	(0.88)	(0.47)	(0.53)	(1.08)
	b) Diluted	(0.15)	(0.32)	(0.88)	(0.47)	(0.53)	(1.08)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	



		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 Months period ended		For the year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
		UN AUDITED	UN AUDITED	Refer No 8	UN AUDITED	Refer No 8	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	897.96	142.86	138.73	1,040.82	298.22	1,441.47
	Other Income	227.72	252.93	238.10	480.65	518.39	1,403.63
	<b>Total income</b>	<b>1,125.68</b>	<b>395.79</b>	<b>376.83</b>	<b>1,521.47</b>	<b>816.61</b>	<b>2,845.10</b>
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	571.74	413.82	459.45	985.56	975.44	1,740.91
	d) Finance costs	26.08	22.43	10.80	48.51	21.70	55.14
	e) Depreciation and amortisation expense	107.46	106.49	141.61	213.95	226.13	416.87
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	1,979.74	1,053.67	1,564.15	3,033.41	5,168.09	10,322.64
	h) Other Expenses	105.78	95.03	223.23	200.81	452.23	949.62
	<b>Total expenses</b>	<b>2,790.80</b>	<b>1,691.44</b>	<b>2,399.24</b>	<b>4,482.24</b>	<b>6,843.59</b>	<b>13,485.18</b>
3	Profit before exceptional items, Tax (1-2)	(1,665.12)	(1,295.65)	(2,022.41)	(2,960.77)	(6,026.98)	(10,640.08)
4	Exceptional Items- (Ref Note:7)	-	-	-	-	-	-
5	Profit before Tax (3-4)	(1,665.12)	(1,295.65)	(2,022.41)	(2,960.77)	(6,026.98)	(10,640.08)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	197.18
	b) Deferred tax	(99.46)	(246.72)	(41.11)	(346.18)	(1,442.38)	(1,415.47)
7	Net Profit/ (Loss) for the period/year(5-6)	(1,565.66)	(1,048.93)	(1,981.30)	(2,614.59)	(4,584.60)	(9,421.79)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(11.35)	(11.35)	(1.06)	(22.70)	(2.12)	(45.41)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.96	3.97	0.37	7.93	0.74	15.87
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(7.39)</b>	<b>(7.38)</b>	<b>(0.69)</b>	<b>(14.77)</b>	<b>(1.38)</b>	<b>(29.54)</b>
9	Total Comprehensive Income for the period ( 7+ 8)	(1,573.05)	(1,056.31)	(1,981.99)	(2,629.36)	(4,585.98)	(9,451.33)
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	-	-	13,062.02
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(1.23)	(0.82)	(1.56)	(2.05)	(3.60)	(7.40)
	b) Diluted	(1.23)	(0.82)	(1.56)	(2.05)	(3.60)	(7.40)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	



**NOTES:-**

- 1) The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 27, 2020. The above results have been subjected to limited review by the statutory auditors of the company.
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the Wholly Owned Subsidiary, Suven Neurosciences, Inc
- 4) The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06, 2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date. The Company (SLSL) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable SPL to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period, the Company is continuing the CRAMS business in its own name on behalf of SPL. However, all such operations were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL.
- 5) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other contents in buildings was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the period ended Sept 30, 2020, the company has written off net book value of assets aggregating Rs 72.65 Lakhs and recognised a minimum insurance claim receivable for equivalent amount .
- 6) The COVID-19 impact on the business and going concern assumption of SLSL and its subsidiary:  
COVID-19 had not impacted the company's research operations, which includes our subsidiary, Suven Neurosciences, Inc.
- 7) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 8) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

**For SUVEN LIFE SCIENCES LTD**



**VENKAT JASTI**  
*Chairman & CEO*  
**DIN: 00278028**

Place: Hyderabad  
Date: October 27, 2020

# SUVEN LIFE SCIENCES LTD

## Unaudited Standalone Cash flow statement

(Rs.In lakhs)

Particulars	For the period ended September 30, 2020	For the period ended September 30, 2019
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	(943.89)	(2,111.20)
<b>Adjustments :</b>		
Depreciation and amortisation expense	172.86	226.13
Interest Income	(450.81)	(448.17)
Finance Cost	47.25	21.01
Unrealised/sale of Gain on Current Investment	(3.66)	(50.97)
<b>Operating profit before working capital changes</b>	<b>(1,178.26)</b>	<b>(2,363.21)</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	(59.22)	124.46
Inventories	(15.04)	-
Other non current assets	29.90	-
Other current financial assets	0.10	-
Other current assets	(261.21)	(230.37)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	(275.80)	(450.74)
Long term provisions	17.21	-
Other non-current liabilities	(14.53)	(14.53)
Short term provision	20.59	23.88
Other financial liabilities	234.41	(104.86)
Other current liabilities	24.83	(9.49)
<b>Cash generated from operating activities</b>	<b>(1,477.03)</b>	<b>(3,024.86)</b>
Income taxes paid (net of refunds)	38.52	37.06
<b>Net Cash flows from operating activities</b>	<b>(1,515.55)</b>	<b>(3,061.92)</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(271.20)	(161.54)
Other non current financial assets	3,623.43	(13,358.62)
Interest received	450.81	448.17
Changes in Investments	(1,650.06)	(6,144.54)
Sale/(purchase) of mutual funds	(499.98)	22,283.51
Bank balances not considered as cash and cash equivalents	0.23	0.03
<b>Net cash flow from /( used in) investing activities</b>	<b>1,653.23</b>	<b>3,067.02</b>
<b>C. Cash flows from financing activities</b>		
(Repayment)/Proceeds from long term borrowings	(36.81)	17.68
Changes In Lease Liability	(26.31)	-
Finance Cost	(47.25)	(21.01)
<b>Net cash flow from /(used In) financing activities</b>	<b>(110.37)</b>	<b>(3.33)</b>
Net increase/(decrease) in cash and cash equivalents	27.31	1.77
Cash and cash equivalents as at the beginning of the year	70.76	1.27
<b>Cash and cash equivalents at the end of the year</b>	<b>98.07</b>	<b>3.04</b>
Cash and cash equivalents	98.07	3.04
Balances per statement of cash flows	98.07	3.04



Place: Hyderabad

Date: October 27, 2020

For Suven Life Sciences Ltd

Venkat Jasti

**Venkat Jasti**  
Chairman & CEO  
DIN: 00278028

# SUVEN LIFE SCIENCES LTD

## Unaudited Consolidated Cash flow statement

(Rs.In lakhs)

Particulars	For the period ended September 30, 2020	For the period ended September 30, 2019
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	(2,960.77)	(6,026.98)
<b>Adjustments :</b>		
Depreciation and amortisation expense	172.86	226.13
Interest Income	(450.81)	(448.17)
Finance Cost	48.51	21.70
Unrealised/sale of Gain on Current Investment	(3.66)	(50.97)
<b>Operating profit before working capital changes</b>	<b>(3,193.88)</b>	<b>(6,278.30)</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	(59.22)	124.46
Inventories	(15.04)	-
Other non current assets	29.90	-
Other current financial assets	2.15	-
Other current assets	(261.21)	(230.43)
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	(275.79)	(450.74)
Long term provisions	17.21	-
Other non-current liabilities	(14.53)	(14.53)
Short term provision	20.59	23.88
Other financial liabilities	(734.21)	(2,231.03)
Other current liabilities	24.83	(9.49)
<b>Cash generated from operating activities</b>	<b>(4,459.21)</b>	<b>(9,066.18)</b>
Income taxes paid (net of refunds)	38.52	37.06
<b>Net Cash flows from operating activities</b>	<b>(4,497.73)</b>	<b>(9,103.23)</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(271.20)	(161.54)
Other non current financial assets	3,623.43	(13,358.62)
Sale/(purchase) of mutual funds	(499.98)	22,283.51
Foreign currency translation reserve	3.62	(34.57)
Bank balances not considered as cash and cash equivalents	0.23	0.03
Interest received	450.81	448.17
<b>Net cash flow from /( used in) investing activities</b>	<b>3,306.91</b>	<b>9,176.99</b>
<b>C. Cash flows from financing activities</b>		
(Repayment)/Proceeds from long term borrowings	(36.81)	17.68
Changes In Lease Liability	(26.31)	-
Finance Cost	(48.51)	(21.70)
<b>Net cash flow from /(used In) financing activities</b>	<b>(111.63)</b>	<b>(4.02)</b>
Net increase/(decrease) in cash and cash equivalents	(1,302.45)	69.73
Cash and cash equivalents as at the beginning of the year	1,467.57	22.75
<b>Cash and cash equivalents at the end of the year</b>	<b>165.12</b>	<b>92.48</b>
Cash and cash equivalents	165.12	92.48
Balances per statement of cash flows	165.12	92.48



Place : Hyderabad  
Date : October 27, 2020

For Suven Life Sciences Ltd

*Venkat Jasti*

**Venkat Jasti**  
Chairman & CEO  
DIN: 00278028



# SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

## Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	30/09/2020	31/03/2020	30/09/2020	31/03/2020
	UN AUDITED	AUDITED	UN AUDITED	AUDITED
<b>A ASSETS</b>				
<b>1 Non-current assets</b>				
(a) Property, Plant and Equipment	1,820.58	2,063.88	1,820.58	2,063.88
(b) Capital Work-in-Progress	269.76	-	269.76	-
(c) Other Intangible Assets	14.36	15.13	14.36	15.13
(d) Right of use Assets	349.27	390.36	349.27	390.36
(e) Financial Assets				
I. Investments	25,831.37	24,181.31	-	-
II. Loans	5,501.82	9,125.25	5,501.82	-
(f) Other Non-current Assets	11.19	-	11.19	9,125.25
<b>Total Non-Current assets</b>	<b>33,798.35</b>	<b>35,775.93</b>	<b>7,966.98</b>	<b>11,594.62</b>
<b>2 Current assets</b>				
<b>Inventories</b>	<b>15.04</b>	<b>-</b>	<b>15.04</b>	<b>-</b>
(a) Financial Assets				
I. Investments	508.58	4.94	508.58	4.94
II. Trade Receivables	286.27	227.05	286.27	227.05
III. Cash and Cash equivalents	98.07	70.76	165.12	1,467.57
IV. Bank balances other than (III) above	41.43	41.65	41.43	41.65
V. Loans	4,200.60	4,200.70	4,200.60	4,200.70
VI. Other Financial assets	-	-	-	2.05
(b) Current Tax asset (net)	496.62	458.10	496.62	458.10
(c) Other current assets	530.42	196.56	530.42	196.56
<b>Total Current assets</b>	<b>6,177.03</b>	<b>5,199.76</b>	<b>6,244.08</b>	<b>6,598.62</b>
<b>TOTAL - ASSETS</b>	<b>39,975.38</b>	<b>40,975.69</b>	<b>14,211.06</b>	<b>18,193.24</b>
<b>B EQUITY AND LIABILITIES</b>				
<b>1 EQUITY</b>				
(a) Equity Share Capital	1,272.82	1,272.82	1,272.82	1,272.82
(b) Other Equity	36,882.04	37,494.53	10,436.28	13,062.02
<b>Total Equity</b>	<b>38,154.86</b>	<b>38,767.35</b>	<b>11,709.10</b>	<b>14,334.84</b>
<b>2 LIABILITIES</b>				
(a) Financial Liabilities				
I. Lease Liabilities	261.94	293.50	261.94	293.50
II. Borrowings	71.68	108.49	71.68	108.49
(b) Provisions	189.27	172.06	189.27	172.06
(c) Other non current liabilities	32.10	46.63	32.10	46.63
(d) Deferred tax Liabilities (net)	232.49	586.60	232.49	586.60
<b>Total non-current liabilities</b>	<b>787.48</b>	<b>1,207.28</b>	<b>787.48</b>	<b>1,207.28</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
I. Lease Liabilities	110.11	104.87	110.11	104.87
II. Trade payables				
a) To Micro & Small Enterprises	16.32	28.42	16.32	28.42
b) Other than Micro & Small Enterprises	286.08	549.78	286.08	549.78
III. Other Financial Liabilities	414.53	180.12	1,095.97	1,830.18
(b) Other Current liabilities	89.40	64.57	89.40	64.57
(c) Provision Employee benefits	116.60	73.30	116.60	73.30
<b>Total - Current liabilities</b>	<b>1,033.04</b>	<b>1,001.06</b>	<b>1,714.48</b>	<b>2,651.12</b>
<b>Total Liabilities</b>	<b>1,820.52</b>	<b>2,208.34</b>	<b>2,501.96</b>	<b>3,858.40</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>39,975.38</b>	<b>40,975.69</b>	<b>14,211.06</b>	<b>18,193.24</b>

Place : Hyderabad  
Date: October 27, 2020



For SUVEN Life Sciences Ltd

Venkat Jasti  
Chairman & CEO  
DIN: 00278028